:415



DECLARATION - USA PATENT APPLICATION

below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled FUSION MOLECULES AND METHODS FOR TREATMENT OF IMMUNE DISEASES; the specification of which was filed on October 24, 2001 as Application Serial No. 10/000,439.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above;

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56;

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below, and insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56, which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Prior U.S.A. Application(s)

Application No.: 09/847,208 Filing Date: May 1, 2001 Status: Pending

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: Andrew Saxon

Inventor's signature _

Residence:

416 15th Street

Santa Monica, CA 90402-2222

Citizenship: U.S. Citizen

Post Office Address: 416 15th Street

Santa Monica, CA 90402-2222

Send Correspondence To: KNOBBE, MARTENS, OLSON & BEAR, LLP Customer No. 20,995

W:\DOCS\EJD\UC067.004A\EJD-1039.DOC 012502

COPY Do Not Record

ASSIGNMENT

U.C. Case No. UC 2001-268-2

O.C. Case No. UC 2001-268-2	
For good and valuable consideration, the receipt of which i	s hereby acknowledged, ASSIGNOR(S),
1. Andrew Saxon 2.	3
hereby sells, assigns and transfers to ASSIGNEE, The Region Corporation, having its statewide administrative offices loc Oakland CA 94607-5200, and the successors, assigns and leright, title and interest for the United States and its territoria to, any and all improvements which are disclosed in the interest of the United States and its territoria to, any and all improvements which are disclosed in the interest of the United States and its territoria to, any and all improvements which are disclosed in the interest of the United States and its territoria to, any and all improvements which are disclosed in the interest of the United States and its territoria to, any and all improvements which are disclosed in the interest of the United States and its territoria to, any and the successors, assigns and the successors are the United States and its territoria to, any and the successors are the United States and its territoria to, any and the successors are the United States and its territoria to, any and the successors are the United States and its territoria to, any and the successors are the United States and its territoria to, any and the successors are the United States and its territoria to, any and the successors are the United States and the United States are the United States and the United States are the United States and the United States are the United States	ated at 1111 Franklin Street, Twelfth Floor, egal representatives of the ASSIGNEE all of its
FUSION MOLECULES AND METHODS FOR T	REATMENT OF IMMUNE DISEASES
And which is found in	
(a) U.S. provisional application filed herewith (b) U.S. patent application filed herewith and (c) X U.S. application serial no. 10/000,439, file (d) U.S. Patent No.:	listing the above named persons as inventors d on October 24, 2001
and any legal equivalent thereof in a foreign country, included Letters Patent to be obtained for said invention by the above continuation-in-part, extension, conversion to 35 USC 111(a reexamination or extension of said Letters Patent and all rig Protection of Industrial Property;	ling the right to claim priority and, in and to, all application or any continuation. Division,
ASSIGNOR(S) hereby covenants that no assignment, sale, a made or entered into which would conflict with this assignment.	ngreement or encumbrance has been or will be nent;
ASSIGNOR(S) further covenants that ASSIGNEE will, upo pertinent facts and documents relating to said invention and may be known and accessible to ASSIGNOR and will testify or proceeding, relating thereto and will promptly execute an representative any all papers, instruments or affidavits requirenforce said application, said invention and said Letters Pate necessary or desirable to carry out the purposes thereof. An by the execution of this assignment to insert into this assignmapplication when officially known.	said Letters Patent and legal equivalents as y as to the same in any interference, litigation, d deliver to ASSIGNEE or its legal red to apply for, obtain, maintain, issue or ent and said equivalents thereof which may be attorney of record is authorized and requested.
AND the ASSIGNOR(S) requests the Commissioner of Pate of the United States and any reissue or extension thereof to t California.	nt and Trademarks to issue said Letters Patent he assignee, The Regents of the University of
Executed this	Signature of Inventor(s)
<u>S</u> day of <u>Feb</u> , 2002	ANDREW SAXON

W:\DOCS\EJD\UC067.004A\EJD-1040.DOC 012502